Aerovate Therapeutics Inc
For the period ended Dec 31, 2023. Filed Mar 25, 2024.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2023 · Filed Mar 25, 2024
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Item 9B. Other Information
(a)
None.
(b)
Rule 10b5-1 Plans
On November 16, 2023, Benjamin Dake, our President, adopted a trading arrangement that is intended to satisfy the affirmative defense of Rule 10b5-1(c) (the Dake 10b5-1 Plan). Between March 18, 2024 and December 31, 2024, the Dake 10b5-1 Plan provides for the potential sale of approximately 193,530 of our common stock. The plan expires on December 31, 2024, or upon the earlier completion of all authorized transactions under the plan.
On November 17, 2023, Marinus Verwijs, our Chief Technology Officer, adopted a trading arrangement that is intended to satisfy the affirmative defense of Rule 10b5-1(c) (the Verwijs 10b5-1 Plan). Between March 19, 2024 and October 1, 2024, the Verwijs 10b5-1 Plan provides for the potential sale of approximately 42,400 of the our common stock. The plan expires on December 31, 2024, or upon the earlier completion of all authorized transactions under the plan.
On November 24, 2023, Timothy Noyes, our Chief Executive Officer, adopted a trading arrangement that is intended to satisfy the affirmative defense of Rule 10b5-1(c) (the Noyes 10b5-1 Plan). Between April 1, 2024 and July 16, 2025, the Noyes 10b5-1 Plan provides for the potential sale of approximately 280,000 of our common stock. The plan expires on July 31, 2025, or upon the earlier completion of all authorized transactions under the plan.
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.